argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

argenx (ARGX) is building a differentiated autoimmune platform, leveraging VYVGART's commercial success into a self-reinforcing growth engine. ARGX delivered 63% YoY sales growth in Q1 2026, maintains 30% operating margins, and funds pipeline expansion without near-term financing risk. The recent FDA approval of VYVGART for all adult gMG patients expands ARGX's addressable market and strengthens its competitive positioning.

Seeking Alpha • 9 hours ago

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

Argenx SE – ADR (NASDAQ:ARGX) shares are up during Monday's session as the company celebrates a recent FDA approval for its drug, VYVGART, which adult patients with generalized myasthenia gravis can use.

Benzinga • May 11, 2026

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART in the ADAPT SERON study experienced rapid, significant and sustained symptom improvements that continued with ongoing treatment Approval advances argenx's commitment to address the unique needs of every MG patient, delivering the broadest MG label to date May 8, 2026, 5:20 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for VYVGART® (efgartigimod alfa-fcab) and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). The approved supplemental Biologics License Application (sBLA) expands VYVGART's indication to include all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.

GlobeNewsWire • May 8, 2026

Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse

Argenx stock rose early Thursday on better-than-expected first-quarter profit, though sales missed some forecasts.

Investors Business Daily • May 7, 2026

argenx SE (ARGX) Q1 2026 Earnings Call Transcript

argenx SE (ARGX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors' appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors.

GlobeNewsWire • May 6, 2026

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.

GlobeNewsWire • May 6, 2026

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • May 4, 2026

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update.

GlobeNewsWire • Apr 30, 2026